Clinicopathological Characteristics of Obesity-associated Focal Segmental Glomerulosclerosis

REFERENCES

• Weisinger JR, Kempson RL, Eldridge FL, Swenson RS. The nephrotic syndrome: a complication of massive obesity. Ann Intern Med. 1974;8:440–447.
   Web of Science ®Google Scholar
• Cohen AH. Massive obesity and the kidney: a morphologic and statistical study. Am J Pathol. 1975;81:117–130.
   PubMedGoogle Scholar
• Praga M, Morales E. Obesity, proteinuria and progression of renal failure. Curr Opin Nephrol Hypertens. 2006;15:481–486.
   PubMed Web of Science ®Google Scholar
• Serra A, Romero R, Lopez D, et al. Renal injury in the extremely obese patients with normal renal function. Kidney Int. 2008;73: 947–955.
   PubMed Web of Science ®Google Scholar
• Praga M, Hernández E, Morales E, et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2001;16:1790–1798.
   PubMedGoogle Scholar
• Kambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001;59:1498–1509.
   PubMed Web of Science ®Google Scholar
• Adelman RD, Restaino IG, Alon US, Blowey DL. Proteinuria and focal segmental glomerulosclerosis in severely obese adolescents. J Pediatr. 2001;138:481–485.
   PubMedGoogle Scholar
• Jennette JC, Charles L, Grubb W. Glomerulomegaly and focal segmental glomerulosclerosis associated with obesity and sleep-apnea syndrome. Am J Kidney Dis. 1987;10:470–472.
   PubMed Web of Science ®Google Scholar
• Verani RR. Obesity-associated focal segmental glomerulosclerosis: pathological feature of the lesion and relationship with cardiomegaly and hyperlipidemia. Am J Kidney Dis. 1992; 20:629–634.
   PubMedGoogle Scholar
• Chen HM, Liu ZH, Zeng C-H, Li SJ, Wang Q-W, Li LS. Podocyte lesions in patients with obesity-related glomerulopathy. Am J Kidney Dis. 2006. 48:772–779.
   PubMedGoogle Scholar
• Chen HM, Li SJ, Chen HP, Wang QW, Li LS, Liu ZH. Obesity-related glomerulopathy in China: a case series of 90 patients. Am J Kidney Dis. 2008;52:58–65.
   PubMedGoogle Scholar
• Henegar JR, Bigler SA, Henegar LK, et al. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol. 2001;12:1211–1217.
   PubMed Web of Science ®Google Scholar
• Goumenos DS, Kawar B, El Nahas M, et al. Early histological changes in the kidney of people with morbid obesity. Nephrol Dial Transplant. 2009; 24:3732–3738.
   PubMedGoogle Scholar
• Kasiske BL, Crosson JT. Renal disease in patients with massive obesity. Arch Intern Med. 1986;146:1105–1109.
   PubMed Web of Science ®Google Scholar
• Praga M, Morales E, Herrero JC, et al. Absence of hypoalbuminemia despite massive proteinuria in focal segmental glomerulosclerosis secondary to hyperfiltration. Am J Kidney Dis. 1999;33:52–58.
   PubMed Web of Science ®Google Scholar
• Rea DJ, Heimbach JK, Grande JP, et al. Glomerular volume and renal histology in obese and non-obese living kidney donors. Kidney Int. 2006;70:1636–1641.
   PubMed Web of Science ®Google Scholar
• Endlich N, Kress KR, Reiser J, et al. Podocytes respond to mechanical stress in vitro. J Am Soc Nephrol. 2001;12:413–422.
   PubMed Web of Science ®Google Scholar
• D’Agati VD, Markowitz GS. Supersized kidneys: lessons from the preclinical obese kidney. Kidney Int. 2008;73:909–910.
   PubMedGoogle Scholar
• Nagata M, Kriz W. Glomerular damage after uninephrectomy in young rats: mechanical stress on podocytes as a pathway to sclerosis. Kidney Int. 1992;42:148–160.
   PubMedGoogle Scholar
• Durvasula RV, Shankland SJ. The renin-angiotensin system in glomerular podocytes: mediator of glomerulosclerosis and link to hypertensive nephropathy. Curr Hypertens Rep. 2006;8:132–138.
   PubMed Web of Science ®Google Scholar
• Gill PS, Wilcox CS. NADPH oxidases in the kidney. Antioxid Redox Signal. 2006;8:1597–1607.
   PubMed Web of Science ®Google Scholar
• Macconi D, Abbate M, Morigi M, et al. Permselective dysfunction of podocyte–podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention. Am J Pathol. 2006;168:1073–1085.
   PubMed Web of Science ®Google Scholar
• Benigni A, Gagliardini E, Remuzzi G. Changes in glomerular perm-selectivity induced by angiotensin II imply podocyte dysfunction and slit diaphragm protein rearrangement. Semin Nephrol. 2004;24:131–140.
   PubMed Web of Science ®Google Scholar
• Miceli I, Burt D, Tarabra E, Camussi G, Perin PC, Gruden G. Stretch reduces nephrin expression via an angiotensin II-AT 1-dependent mechanism in human podocytes: effect of rosiglitazone. Am J Physiol Renal Physiol. 2009;298:F381–F390
   Google Scholar
• Chen S, Lee JS, Iglesias-de la Cruz MC, et al. Angiotensin II stimulates alpha3(IV) collagen production in mouse podocytes via TGF-beta and VEGF signalling: implications for diabetic glomerulopathy. Nephrol Dial Transplant. 2005;20:1320–1328.
   PubMedGoogle Scholar
• Dessapt C, Baradez MO, Hayward A, et al. Mechanical forces and TGFbeta1 reduce podocyte adhesion through alpha3beta1 integrin downregulation. Nephrol Dial Transplant. 2009;24: 2645–2655.
   PubMedGoogle Scholar
• Chen S, Kasama Y, Lee JS, Jim B, Marin M, Ziyadeh FN. Podocyte-derived vascular endothelial growth factor mediates the stimulation of alpha3(IV) collagen production by transforming growth factor-beta1 in mouse podocytes. Diabetes. 2004;53:2939–2949.
   PubMed Web of Science ®Google Scholar
• Kang YS, Park YG, Kim BK, et al. Angiotensin II stimulates the synthesis of vascular endothelial growth factor through the p38 mitogen activated protein kinase pathway in cultured mouse podocytes. J Mol Endocrinol. 2006;36:377–388.
   PubMed Web of Science ®Google Scholar
• Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabet Rev. 2008;4:39–45.
   PubMedGoogle Scholar
• Yoshida S, Nagase M, Shibata S, Fujita T. Podocyte injury induced by albumin overload in vivo and in vitro: Involvement of TGF-beta and p38 MAPK. Nephron Exp Nephrol. 2008;108:e57–e68.
   Google Scholar
• Petermann AT, Pippin J, Durvasula R, et al. Mechanical stretch induces podocyte hypertrophy in vitro. Kidney Int. 2005;67:157–166.
   PubMedGoogle Scholar
• Xu ZG, Yoo TH, Ryu DR, et al. Angiotensin II receptor blocker inhibits p27Kip1 expression in glucose-stimulated podocytes and in diabetic glomeruli. Kidney Int. 2005;67:944–952.
   PubMedGoogle Scholar
• Zhu WW, Chen HP, Ge YC, et al. Ultrastructural changes in the glomerular filtration barrier and occurrence of proteinuria in Chinese patients with type 2 diabetic nephropathy. Diabetes Res Clin Pract. 2009;86:199–207.
   PubMedGoogle Scholar
• Mundel P, Sharkland SJ. Podocyte biology and response to injury. Am Soc Nephrol. 2002;13:3005–3015.
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Ruilope LM. Insulin resistance, hyperinsulinemia and renal injury: mechanisms and implications. Am J Nephrol. 2006;26:232–244.
   PubMed Web of Science ®Google Scholar
• Kiyomoto H, Rafiq K, Mostofa M, Nishiyama A. Possible underlying mechanisms responsible for aldosterone and mineralocorticoid receptor-dependent renal injury. J Pharmacol Sci. 2008;108: 399–405.
   PubMed Web of Science ®Google Scholar
• Nishiyama A, Kobori H, Konishi Y, et al. Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats. J Pharmacol Exp Ther. 2010;332:1072–1080.
   PubMed Web of Science ®Google Scholar
• Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension. 2007;49:355–364.
   PubMed Web of Science ®Google Scholar
• Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes. 2007;56:1010–1013.
   PubMed Web of Science ®Google Scholar
• Takano Y, Yamauchi K, Hayakawa K, et al. Transcriptional suppression of nephrin in podocytes by macrophages: roles of inflammatory cytokines and involvement of the PI3K/Akt pathway. FEBS Lett. 2007;581:421–426.
   PubMed Web of Science ®Google Scholar
• Wu Y, Liu Z, Xiang Z, et al. Obesity-related glomerulopathy: insights from gene expression profiles of the glomeruli derived from renal biopsy samples. Endocrinology. 2006; 147:44–50
   PubMed Web of Science ®Google Scholar
• Praga M, Hernandez E, Andres A, Leon M, Ruilope LM, Rodicio JL. Effects of body-weight loss and captopril treatment on proteinuria associated with obesity. Nephron. 1995;70(1):35e41.
   Google Scholar
• Fowler SM, Kon V, Ma L, Richards WO, Fogo AB, Hunley TE. Obesity-related focal and segmental glomerulosclerosis: normalization of proteinuria in an adolescent after bariatric surgery. Pediatr Nephrol. 2009;24:851–855.
   PubMedGoogle Scholar
• Reiser J, Gupta V, Kistler AD. Toward the development of podocyte-specific drugs. Kidney Int. 2010;77:662–668.
   PubMedGoogle Scholar